Appili Therapeutics Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APLIF research report →
About the company
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as ATI-1501, ATI-1503, and ATI-1701.
- CEO
- Don Cilla
- IPO
- 2021
- Employees
- 7
- HQ
- Halifax, NS, CA
Price Chart
- Market Cap
- $1.46M
- P/E
- -0.47
- P/S
- 7.61
- P/B
- -0.11
- EV/EBITDA
- -2.99
- Div Yield
- 0.00%
- Gross Margin
- 96.90%
- Op Margin
- -2116.91%
- Net Margin
- -1622.17%
- ROE
- 26.47%
- ROIC
- 125.67%
- Revenue
- $244.81K · 143.73%
- Net Income
- $-4,251,698 · -61.99%
- EPS
- $-0.03 · -59.26%
- Op Income
- $-6,550,229
- FCF YoY
- -260.15%
- 52W High
- $0.03
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -0.21
- Avg Volume
- 19.68K
Get TickerSpark's AI analysis on APLIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our APLIF coverage
Recent articles, reports, and earnings notes.
No research on APLIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APLIF report →Similar companies
Peers in the same neighborhood.